Search This Blog

Tuesday, November 2, 2021

Fresenius Medical Care cuts jobs as Delta variant takes toll

 

German dialysis specialist Fresenius Medical Care (FMC) plans to cut costs and up to 5,000 jobs globally - or about 4% of its workforce - as the Delta variant caused another spike in coronavirus-related patient deaths in the third quarter.

FMC had expected the death toll among dialysis patients, who are more susceptible to the virus, to normalise during the second half of the year, but said on Tuesday it now saw a decline in the mortality rate only in the fourth quarter.

"The existence of the Delta variant has caused excess mortality among our patients to rise again in the third quarter," Chief Executive Rice Powell said.

"This means that we must absorb a sizeably larger COVID-19 effect on our business than we projected at the beginning of the year."

The world's largest provider of dialysis treatments aims to reach annual cost cuts of 500 million euros ($580 million) by 2025, as it plans to replace its four regions and some global functions with two divisions: care enablement and care delivery.

Fresenius group, FMC's parent company, had previously announced plans to cut spending by 100 million euros a year in 2021-2025.

FMC maintained its forecast for net income to decline by a high-teens to mid-twenties percentage and sales growth in the low- to mid-single-digits, but warned the numbers would come in the lower end of the ranges.

Fresenius group firmed up its 2021 net income forecast after reporting quarterly results slightly above expectations.

JP Morgan analysts said Fresenius reported "a solid set of results" that should drive the shares today. "However, our concern on outer-year forecasts for FMC leaves us cautious on how much the shares can progress from here."

https://www.marketscreener.com/quote/stock/FRESENIUS-MEDICAL-CARE-AG-436087/news/Fresenius-Medical-Care-cuts-jobs-as-Delta-variant-takes-toll-36863172/

Lilly to supply additional bamlanivimab and etesevimab to U.S. for Covid treatment, post-exposure prevention

  Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain individuals. As part of the agreement, Lilly will supply 614,000 doses of bamlanivimab with etesevimab no later than January 31, 2022 for a total of $1.29 billion. A minimum of 400,000 doses will be supplied no later than December 31, 2021.

The estimated impact of the new purchase to the 2021 guidance provided in Lilly's earnings release dated October 26, 2021 is $840 million of additional revenue and approximately 25 cents of additional earnings per share. The expected impact in 2022 will be reflected in the company's financial guidance to be provided in December 2021. 

http://kokomoperspective.com/politics/indiana/lilly-to-supply-614-000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-u-s/article_789b1213-a2bf-5889-a045-49abc5ac195b.html

Pfizer raises Covid vaccine sales forecast to $36 billion for 2021

 

  • Pfizer on Tuesday raised the full-year sales forecast for its Covid-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.
  • The company said it is also on track to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it plans to make this year.
  • The vaccine brought in sales of $13 billion in the third quarter. Analysts had expected $10.88 billion on average, according to seven analysts polled by Refinitiv.
  • Pfizer on Tuesday raised the full-year sales forecast for its Covid-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.

    The company said it is also on track to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it plans to make this year.

    Driven by an unprecedented vaccination drive against the Covid-19 pandemic globally, Pfizer’s shot has quickly become one of the best-selling products in the company’s roughly 172-year history. The company equally splits expenses and profit from the vaccine with its German partner BioNTech.

    Other rivals such as Moderna and Johnson & Johnson have faced production snags, helping Pfizer extend its lead in signing supply deals with countries.

    Pfizer is also rolling out booster doses of the vaccine, while waiting for the outcome of a U.S. regulatory meeting later in the day on using its shots in children aged five to 11.

    The vaccine brought in sales of $13 billion in the third quarter. Analysts had expected $10.88 billion on average, according to seven analysts polled by Refinitiv.

  • https://www.cnbc.com/2021/11/02/pfizer-raises-covid-vaccine-sales-forecast-to-36-billion-.html

California judge delivers drugmakers 1st trial win in opioid litigation

 A California judge on Monday said he would rule against several large counties that accused four drugmakers of fueling the U.S. opioid epidemic, saying they failed during a trial to prove their $50 billion case.

Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson (JNJ.N), Teva Pharmaceutical Industries Ltd (TEVA.TA), Endo International PLC (ENDP.O) and AbbVie Inc's (ABBV.N) Allergan unit not liable.

It marked the first trial win for any drug companies in the more than 3,300 lawsuits filed by states and local governments over a drug abuse crisis that the U.S. government says led to nearly 500,000 opioid overdose deaths over two decades

The ruling came as J&J and the three largest U.S. drug distributors - McKesson Corp, Cardinal Health Inc and AmersourceBergen -- work to finalize a proposed deal to pay up to $26 billion to settle the thousands of cases against them.

A bankruptcy judge in August approved a settlement by OxyContin maker Purdue Pharma and its wealthy Sackler family owners of the claims against them that the company values at more than $10 billion.

During a months-long, non-jury trial, the populous Santa Clara, Los Angeles and Orange counties and the city of Oakland argued the drugmakers' marketing downplayed opioids' addictive risks and promoted them for broader uses than intended.

They argued the advertising led to billions of pain pills flooding their communities and a rise in overdose deaths. They said the companies should pay more than $50 billion to cover the costs of abating the public nuisance they created, plus penalties.

But Wilson said even if the drugmakers' marketing contained any misleading statements, the counties put forward no evidence to show that their promotional activities caused any medically inappropriate prescriptions to be written.

He agreed with the companies that the epidemic could not be considered a legal public nuisance because the federal government and the state had at the time determined the benefits of medically appropriate prescriptions outweighed their harms.

"There is simply no evidence to show that the rise in prescriptions was not the result of the medically appropriate provision of pain medications to patients in need," Wilson wrote.

J&J in a statement said the decision showed its marketing was "appropriate and responsible." John Hueston, Endo's lawyer, said it demonstrated his client's "lawful conduct did not cause the widespread public nuisance at issue in plaintiffs' complaint."

Teva in a statement said it continues to pursue a national settlement framework and that the ruling was a "clear win" for patients who would benefit from comprehensive settlements being finalized.

Representatives for the California plaintiffs did not respond to requests for comment. They could potentially challenge the tentative ruling before it becomes final. Tentative decisions are typical in California state courts.

In a statement, the lead lawyers overseeing related federal lawsuits against the companies -- Jayne Conroy, Paul Farrell and Joe Rice -- said they strongly disagreed with the ruling and stressed that it did not impact related cases nationally.

The only other opioid trial to reach a verdict resulted in an Oklahoma judge in 2019 ordering J&J to pay $465 million to the state. J&J is appealing that decision.

Trials are currently underway a New York case against Teva and AbbVie and in Ohio against three pharmacy chain operators. A West Virginia federal judge recently finished hearing evidence in a trial involving the distributors.

https://www.reuters.com/world/us/california-judge-rules-drugmakers-major-opioid-lawsuit-2021-11-02/

Monday, November 1, 2021

'Boosting human mental function with brain stimulation'

 In a pilot human study, researchers from the University of Minnesota Medical School and Massachusetts General Hospital show it is possible to improve specific human brain functions related to self-control and mental flexibility by merging artificial intelligence with targeted electrical brain stimulation.

Alik Widge, MD, PhD, an assistant professor of psychiatry and member of the Medical Discovery Team on Addiction at the U of M Medical School, is the senior author of the research published in Nature Biomedical Engineering. The findings come from a human study conducted at Massachusetts General Hospital in Boston among 12 patients undergoing brain surgery for epilepsy -- a procedure that places hundreds of tiny electrodes throughout the brain to record its activity and identify where seizures originate.

In this study, Widge collaborated with Massachusetts General Hospital's Sydney Cash, MD, PhD, an expert in epilepsy research; and Darin Dougherty, MD, an expert in clinical brain stimulation. Together, they identified a brain region -- the internal capsule -- that improved patients' mental function when stimulated with small amounts of electrical energy. That part of the brain is responsible for cognitive control -- the process of shifting from one thought pattern or behavior to another, which is impaired in most mental illnesses.

"An example might include a person with depression who just can't get out of a 'stuck' negative thought. Because it is so central to mental illness, finding a way to improve it could be a powerful new way to treat those illnesses," Widge said.

The team developed algorithms, so that after stimulation, they could track patients' cognitive control abilities, both from their actions and directly from their brain activity. The controller method provided boosts of stimulation whenever the patients were doing worse on a laboratory test of cognitive control.

"This system can read brain activity, 'decode' from that when a patient is having difficulty, and apply a small burst of electrical stimulation to the brain to boost them past that difficulty," Widge said. "The analogy I often use is an electric bike. When someone's pedaling but having difficulty, the bike senses it and augments it. We've made the equivalent of that for human mental function."

The study is the first to show that:

  • A specific human mental function linked to mental illness can be reliably enhanced using precisely targeted electrical stimulation;
  • There are specific sub-parts of the internal capsule brain structure that are particularly effective for cognitive enhancement; and
  • A closed-loop algorithm used as a controller was twice as effective than stimulating at random times.

Some of the patients had significant anxiety in addition to their epilepsy. When given the cognitive-enhancing stimulation, they reported that their anxiety got better, because they were more able to shift their thoughts away from their distress and focus on what they wanted. Widge says that this suggests this method could be used to treat patients with severe and medication-resistant anxiety, depression or other disorders.

"This could be a totally new approach in treating mental illness. Instead of trying to suppress symptoms, we could give patients a tool that lets them take control of their own minds," Widge said. "We could put them back in the driver's seat and let them feel a new sense of agency."

The research team is now preparing for clinical trials. Because the target for improving cognitive control is already approved by the Food and Drug Administration for deep brain stimulation, Widge says this research can be done with existing tools and devices -- once a trial is formally approved -- and the translation of this care to current medical practice could be rapid.

"The wonderful thing about these findings is that we are now in a position to conduct clinical trials to further demonstrate effectiveness and then hopefully move to helping treatment-resistant patients who are in desperate need for additional interventions to treat their illnesses," Dougherty said.

This work was supported by grants from the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement Number W911NF-14-2-0045 issued by the Army Research Organization (ARO) contracting office in support of DARPA's SUBNETS Program, the National Institutes of Health, Ellison Foundation, Tiny Blue Dot Foundation, MGH Executive Council on Research, OneMind Institute and the MnDRIVE and Medical Discovery Team on Addiction initiatives at the University of Minnesota Medical School.


Story Source:

Materials provided by University of Minnesota Medical SchoolNote: Content may be edited for style and length.


Journal Reference:

  1. Ishita Basu, Ali Yousefi, Britni Crocker, Rina Zelmann, Angelique C. Paulk, Noam Peled, Kristen K. Ellard, Daniel S. Weisholtz, G. Rees Cosgrove, Thilo Deckersbach, Uri T. Eden, Emad N. Eskandar, Darin D. Dougherty, Sydney S. Cash, Alik S. Widge. Closed-loop enhancement and neural decoding of cognitive control in humansNature Biomedical Engineering, 2021; DOI: 10.1038/s41551-021-00804-y

In COVID-19 vaccinated people, those with prior infection likely to have more antibodies

 In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable -- that is, remain higher over an extended period of time -- in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

A research letter detailing the study of nearly 2,000 health care workers appears today in the Journal of the American Medical Association.

"This finding adds to our understanding of how immunity against SARS-CoV-2 works, and builds upon an earlier study by our team that showed the mRNA vaccines yielded a robust antibody response, even if a person did not develop significant symptoms following vaccination or did not have a prior SARS-CoV-2 infection," says study senior author Aaron Milstone, M.D., M.H.S., professor of pediatrics at the Johns Hopkins University School of Medicine and pediatric epidemiologist at Johns Hopkins Children's Center.

The two mRNA vaccines evaluated in the study introduce the body's immune system to S1, a protein subunit that's a component of the spikes found on the surface of SARS-CoV-2. The spikes enable the virus to latch onto healthy cells and infect them. Immunoglobulin G antibodies, elicited by S1 from the vaccines stimulating the immune system, neutralize the virus particles, preventing infection by SARS-CoV-2, or at least, reducing the severity of the disease.

For their latest study, the researchers followed 1,960 Johns Hopkins Medicine health care workers who had received both doses of either the Pfizer/BioNTech or Moderna vaccines, including 73 people who had a positive SARS-CoV-2 polymerase chain reaction (PCR) test result before the first vaccine dose. The 73 were divided into two groups -- those who were infected at 90 days or closer to the first vaccine dose, and those whose exposure to the virus was more than 90 days before the initial shot.

After adjusting for vaccine type, age and sex, antibody levels were compared for those with and without prior SARS-CoV-2 infection at one, three and six months following the second vaccine dose. In addition, antibody levels were compared at one and three months following the second dose between the two groups with prior SARS-CoV-2 infection.

"We found that health care workers with prior SARS-CoV-2 infection followed by two doses of mRNA vaccine -- therefore, three independent exposures to the S1 spike protein -- developed higher antibody levels than those with vaccination alone," says study lead author Diana Zhong, M.D., an infectious diseases fellow at the Johns Hopkins University School of Medicine. "The relative differences were 14% higher at 1 month following the second vaccine dose, 19% at three months and 56% at six months."

Zhong adds that the study participants with a PCR-confirmed SARS-CoV-2 infection more than 90 days before their initial vaccination had adjusted antibody levels 9% (one month following the second vaccine dose) and 13% (three months following the second vaccine dose) higher than those who were exposed to the virus less than or equal to the 90-day mark.

"This suggests that a longer interval between infection and first vaccine dose may enhance the antibody response," says Milstone.

Milstone says further investigation is needed to determine whether increased post-vaccination durability in previously infected people is attributable to the number of exposures to the virus, the interval between exposures, or the interplay between natural or vaccine-derived immunity.

The study team at Johns Hopkins Medicine was co-led by Zhong and Shaoming Xiao. Along with them and Milstone, the team includes Amanda Debes, Emily Egbert, Patrizio Caturegli and Elizabeth Colantuoni.

This study was supported by National Institute of Allergy and Infectious Diseases/National Institutes of Health grants T32AI007291 and K24AI141580, along with contributions to the COVID-19 research funds of the Johns Hopkins University School of Medicine and the Johns Hopkins Health System.


Story Source:

Materials provided by Johns Hopkins MedicineNote: Content may be edited for style and length.


Journal Reference:

  1. Diana Zhong, Shaoming Xiao, Amanda K. Debes, Emily R. Egbert, Patrizio Caturegli, Elizabeth Colantuoni, Aaron M. Milstone. Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior InfectionJAMA, 2021; DOI: 10.1001/jama.2021.19996

SARS-CoV-2 virus can infect inner ear

 Many Covid-19 patients have reported symptoms affecting the ears, including hearing loss and tinnitus. Dizziness and balance problems can also occur, suggesting that the SARS-CoV-2 virus may be able to infect the inner ear.

A new study from MIT and Massachusetts Eye and Ear provides evidence that the virus can indeed infect cells of the inner ear, including hair cells, which are critical for both hearing and balance. The researchers also found that the pattern of infection seen in human inner ear tissue is consistent with the symptoms seen in a study of 10 Covid-19 patients who reported a variety of ear-related symptoms.

The researchers used novel cellular models of the human inner ear that they developed, as well as hard-to-obtain adult human inner ear tissue, for their studies. The limited availability of such tissue has hindered previous studies of Covid-19 and other viruses that can cause hearing loss.

"Having the models is the first step, and this work opens a path now for working with not only SARS-CoV-2 but also other viruses that affect hearing," says Lee Gehrke, the Hermann L.F. von Helmholtz Professor in MIT's Institute for Medical Engineering and Science, who co-led the study.

Konstantina Stankovic, a former associate professor at Harvard Medical School and former chief of otology and neurotology at Massachusetts Eye and Ear, who is now the Bertarelli Foundation Professor and chair of the Department of Otolaryngology -- Head and Neck Surgery at Stanford University School of Medicine, co-led the study. Minjin Jeong, a former postdoc in Stankovic's laboratory at Harvard Medical School, who is now at Stanford Medical School, is the lead author of the paper, which appears today in Communications Medicine.

Models of ear infection

Before the Covid-19 pandemic began, Gehrke and Stankovic began working together on a project to develop cellular models to study infections of the human inner ear. Viruses such as cytomegalovirus, mumps virus, and hepatitis viruses can all cause deafness, but exactly how they do so is not well-understood.

In early 2020, after the SARS-CoV-2 virus emerged, the researchers altered their plans. At Massachusetts Eye and Ear, Stankovic started to see patients who were experiencing hearing loss, tinnitus, and dizziness, who had tested positive for Covid-19. "It was very unclear at the time whether this was causally related or coincidental, because hearing loss and tinnitus are so common," she recalls.

She and Gehrke decided to use the model system they were working on to study infection of SARS-CoV-2. They created their cellular models by taking human skin cells and transforming them into induced pluripotent stem cells. Then, they were able to stimulate those cells to differentiate into several types of cells found in the inner ear: hair cells, supporting cells, nerve fibers, and Schwann cells, which insulate neurons.

These cells could be grown in a flat, two-dimensional layer or organized into three-dimensional organoids. In addition, the researchers were able to obtain samples of hard-to-obtain inner ear tissue from patients who were undergoing surgery for a disorder that causes severe attacks of vertigo or for a tumor that causes hearing loss and dizziness.

In both the human inner ear samples and the stem-cell-derived cellular models, the researchers found that certain types of cells -- hair cells and Schwann cells -- express the proteins that are needed for the SARS-CoV-2 virus to enter the cells. These proteins include the ACE2 receptor, which is found on cell surfaces, and two enzymes called furin and transmembrane protease serine 2, which help the virus to fuse with the host cell.

The researchers then showed that the virus can actually infect the inner ear, specifically the hair cells and, to a lesser degree, Schwann cells. They found that the other cell types in their models were not susceptible to SARS-CoV-2 infection.

The human hair cells that the researchers studied were vestibular hair cells, which are involved in sensing head motion and maintaining balance. Cochlear hair cells, which are involved in hearing, are much harder to obtain or generate in a cellular model. However, the researchers showed that cochlear hair cells from mice also have proteins that allow SARS-CoV-2 entry.

Viral connection

The pattern of infection that the researchers found in their tissue samples appears to correspond to the symptoms observed in a group of 10 Covid-19 patients who reported ear-related symptoms following their infection. Nine of these patients suffered from tinnitus, six experienced vertigo, and all experienced mild to profound hearing loss.

Damage to cochlear hair cells, which can cause hearing loss, is usually evaluated by measuring otoacoustic emissions -- sounds given off by sensory hair cells as they respond to auditory stimulation. Among the six Covid-19 patients in the study who underwent this testing, all had reduced or absent otoacoustic emissions.

While this study strongly suggests that Covid-19 can cause auditory and balance problems, the overall percentage of Covid-19 patients who have experienced ear-related issues is not known.

"Initially this was because routine testing was not readily available for patients who were diagnosed with Covid, and also, when patients were having more life-threatening complications, they weren't paying much attention to whether their hearing was reduced or whether they had tinnitus," Stankovic says. "We still don't know what the incidence is, but our findings really call for increased attention to audiovestibular symptoms in people with Covid exposure."

Possible routes for the virus to enter the ears include the Eustachian tube, which connects the nose to the middle ear. The virus may also be able to escape from the nose through small openings surrounding the olfactory nerves, Stankovic says. That would allow it to enter the brain space and infect cranial nerves, including the one that connects to the inner ear.

The researchers now hope to use their human cellular models to test possible treatments for the inner ear infections caused by SARS-CoV-2 and other viruses.

The research was funded by the National Institutes of Health, the Remondi Foundation, the Nancy Sayles Day Foundation, and the Barnes Foundation.


Story Source:

Materials provided by Massachusetts Institute of Technology. Original written by Anne Trafton. Note: Content may be edited for style and length.


Journal Reference:

  1. Minjin Jeong, Karen E. Ocwieja, Dongjun Han, P. Ashley Wackym, Yichen Zhang, Alyssa Brown, Cynthia Moncada, Andrea Vambutas, Theodore Kanne, Rachel Crain, Noah Siegel, Valerie Leger, Felipe Santos, D. Bradley Welling, Lee Gehrke, Konstantina M. Stankovic. Direct SARS-CoV-2 infection of the human inner ear may underlie COVID-19-associated audiovestibular dysfunctionCommunications Medicine, 2021; 1 (1) DOI: 10.1038/s43856-021-00044-w